Want to see FR:ALINS full AI Analyst Report?
Top Page
Intrasense SA
(ALINS)
Select Model
Select Model
Rating:41Neutral
Price Target:
€0.24
▲(3.04% Upside)
Action:Upgraded
Date:01/15/26
The score is primarily held down by weak financial performance—declining revenue, negative margins, ongoing losses, high leverage, and negative operating/free cash flow. Technicals add modest support in the very short term but remain broadly weak versus longer-term moving averages and negative MACD. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Recurring subscription model
A subscription-based licensing model creates recurring revenue and service relationships with healthcare institutions. Over months this improves revenue predictability, supports multi-year customer retention, and can enable more stable cash flow to fund product development and support investments.
Negative Factors
Negative margins and operating losses
Negative gross and net margins and persistent operating losses indicate the core business is not yet profitable. Over months this erodes reserves, limits reinvestment capacity, and makes breakeven harder to reach without sustained margin improvement or cost structure changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring subscription model
A subscription-based licensing model creates recurring revenue and service relationships with healthcare institutions. Over months this improves revenue predictability, supports multi-year customer retention, and can enable more stable cash flow to fund product development and support investments.
Read all positive factors
Intrasense SA (ALINS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€13.88M
Dividend YieldN/A
Average Volume (3M)301.08K
Price to Earnings (P/E)―
Beta (1Y)-0.28
Revenue Growth31.94%
EPS Growth-90.36%
CountryFR
Employees76
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.12
Shares Outstanding52,806,030
10 Day Avg. Volume123,162
30 Day Avg. Volume301,084
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)7.33
Price to Sales (P/S)5.40
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€6.96M
Intrasense SA Business Overview & Revenue Model
Company Description
Established in 2004 and headquartered in Montpellier, France, Intrasense S.A. specializes in the global development of sophisticated software for visualizing and analyzing diverse medical imaging data, marketed under its Myrian brand. The company'...
How the Company Makes Money
Intrasense generates revenue primarily through the sale and licensing of its software solutions to healthcare institutions, including hospitals and imaging centers. The company employs a subscription-based model for its software, which provides a ...
Intrasense SA Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.65M | 2.25M | 3.31M | 3.79M | 4.19M | 3.44M |
| Gross Profit | -6.07M | -3.81M | -885.00K | -1.15M | -1.05M | -454.00K |
| EBITDA | -5.37M | -4.60M | -2.68M | -2.09M | -611.00K | -30.00K |
| Net Income | -6.48M | -5.66M | -3.58M | -3.42M | -1.20M | -704.00K |
Balance Sheet | ||||||
| Total Assets | 9.19M | 7.68M | 10.45M | 6.51M | 8.77M | 6.36M |
| Cash, Cash Equivalents and Short-Term Investments | 1.44M | 930.00K | 4.55M | 1.41M | 4.76M | 2.59M |
| Total Debt | 1.37M | 1.58M | 1.49M | 2.06M | 1.93M | 2.26M |
| Total Liabilities | 10.36M | 6.03M | 3.17M | 4.50M | 3.78M | 4.21M |
| Stockholders Equity | -1.16M | 1.65M | 7.29M | 2.01M | 4.99M | 2.15M |
Cash Flow | ||||||
| Free Cash Flow | -6.50M | -5.94M | -4.97M | -3.48M | -1.50M | -1.08M |
| Operating Cash Flow | -4.62M | -3.73M | -3.05M | -2.00M | -948.00K | -481.00K |
| Investing Cash Flow | -1.86M | -2.21M | -1.93M | -1.49M | -555.00K | -551.00K |
| Financing Cash Flow | 6.61M | 2.33M | 8.10M | 98.00K | 3.62M | 2.71M |
Intrasense SA Technical Analysis
Positive
0.23
Price Trends
0.24
Positive
0.24
Positive
0.24
Positive
Market Momentum
<0.01
Positive
51.21
Neutral
35.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALINS, the sentiment is Positive. The current price of 0.23 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.24, and below the 200-day MA of 0.24, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 51.21 is Neutral, neither overbought nor oversold. The STOCH value of 35.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALINS.
Intrasense SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | €141.53M | -9.64 | -5.44% | 2.17% | -0.81% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €51.34M | -6.29 | 222.05% | ― | 42.86% | 13.93% | |
46 Neutral | €22.10M | -5.13 | -22.03% | ― | 37.28% | 7.83% | |
45 Neutral | €194.33M | -3.44 | 90.10% | ― | 1.79% | 15.89% | |
41 Neutral | €13.88M | -1.29 | 283.66% | ― | 31.94% | -90.36% |
* Healthcare Sector Average
FR:ALINS
Intrasense SA
0.26
-0.03
-11.45%
FR:ALCGM
Cegedim
10.32
0.12
1.18%
FR:ALTHE
Theraclion SA
0.69
-0.01
-2.00%
FR:ALDMS
Diagnostic Medical Systems
0.99
-0.37
-27.06%
FR:ALIKO
Ikonisys SA
1.40
-0.12
-7.89%
FR:ALMDT
Median Technologies
3.96
0.69
21.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.